Pharmacogenomics in the treatment of narcolepsy.

Details

Serval ID
serval:BIB_3EFA9EA221F9
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Pharmacogenomics in the treatment of narcolepsy.
Journal
Pharmacogenomics
Author(s)
Tafti M., Dauvilliers Y.
ISSN
1462-2416[print], 1462-2416[linking]
Publication state
Published
Issued date
01/2003
Volume
4
Number
1
Pages
23-33
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Abstract
Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness and cataplexy. Available treatments of narcolepsy include stimulants and antidepressants but the recent discovery of orexin/hypocretin deficiency in narcolepsy opens up new perspectives. Narcolepsy is a complex disorder involving genetic, immune and environmental factors. Although only a strong association is found with the HLA DQB1*0602 gene, other genetic susceptibility factors might be involved. Among these, the functional polymorphism of the catechol-O-methyltransferase (COMT) gene is critically involved in the severity of narcolepsy and in the response to the stimulant modafinil. Other pharmacogenetic targets include the orexinergic, noradrenergic and possibly the serotonergic pathways.
Keywords
Carrier Proteins/genetics, Catechol O-Methyltransferase/genetics, HLA-DQ Antigens/genetics, Humans, Intracellular Signaling Peptides and Proteins, Narcolepsy/drug therapy, Narcolepsy/genetics, Neuropeptides/genetics, Pharmacogenetics/trends, Polymorphism, Genetic
Pubmed
Web of science
Create date
24/01/2008 15:55
Last modification date
20/08/2019 13:35
Usage data